|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
McMeekin DS, Filiaci VL, Thigpen JT,
Gallion HH, Fleming GF and Rodgers WH: The relationship between
histology and outcome in advanced and recurrent endometrial cancer
patients participating in first-line chemotherapy trials: a
Gynecologic Oncology Group study. Gynecol Oncol. 106:16–22. 2007.
View Article : Google Scholar
|
|
3
|
Oda K, Stokoe D, Taketani Y and McCormick
F: High frequency of coexistent mutations of PIK3CA and
PTEN genes in endometrial carcinoma. Cancer Res.
65:10669–10673. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oda K, Okada J, Timmerman L, et al: PIK3CA
cooperates with other phosphatidylinositol 3′-kinase pathway
mutations to effect oncogenic transformation. Cancer Res.
68:8127–8136. 2008.
|
|
5
|
Shoji K, Oda K, Nakagawa S, et al: The
oncogenic mutation in the pleckstrin homology domain of AKT1 in
endometrial carcinomas. Br J Cancer. 101:145–148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Murayama-Hosokawa S, Oda K, Nakagawa S, et
al: Genome-wide single-nucleotide polymorphism arrays in
endometrial carcinomas associate extensive chromosomal instability
with poor prognosis and unveil frequent chromosomal imbalances
involved in the PI3-kinase pathway. Oncogene. 29:1897–1908. 2010.
View Article : Google Scholar
|
|
7
|
Ikeda Y, Oda K, Nakagawa S, et al:
Genome-wide single nucleotide polymorphism arrays as a diagnostic
tool in patients with synchronous endometrial and ovarian cancer.
Int J Gynecol Cancer. 22:725–731. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kato J, Matsushime H, Hiebert SW, Ewen ME
and Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene
product (pRb) and pRb phosphorylation by the cyclin D-dependent
kinase CDK4. Genes Dev. 7:331–342. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lundberg AS and Weinberg RA: Functional
inactivation of the retinoblastoma protein requires sequential
modification by at least two distinct cyclin-cdk complexes. Mol
Cell Biol. 18:753–761. 1998.
|
|
11
|
Tetsu O and McCormick F: β-Catenin
regulates expression of cyclin D1 in colon carcinoma cells. Nature.
398:422–426. 1999.
|
|
12
|
Albanese C, Johnson J, Watanabe G, et al:
Transforming p21ras mutants and c-Ets-2 activate the cyclin D1
promoter through distinguishable regions. J Biol Chem.
270:23589–23597. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Musgrove EA, Caldon CE, Barraclough J,
Stone A and Sutherland RL: Cyclin D as a therapeutic target in
cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Knudsen KE, Diehl JA, Haiman CA and
Knudsen ES: Cyclin D1: polymorphism, aberrant splicing and cancer
risk. Oncogene. 25:1620–1628. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Solomon DA, Wang Y, Fox SR, et al: Cyclin
D1 splice variants. Differential effects on localization, RB
phosphorylation, and cellular transformation. J Biol Chem.
278:30339–30347. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu F, Gladden AB and Diehl JA: An
alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear
oncogene. Cancer Res. 63:7056–7061. 2003.PubMed/NCBI
|
|
17
|
Kang S, Kim JW, Park NH, Song YS, Kang SB
and Lee HP: Cyclin D1 polymorphism and the risk of endometrial
cancer. Gynecol Oncol. 97:431–435. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Benzeno S, Lu F, Guo M, et al:
Identification of mutations that disrupt phosphorylation-dependent
nuclear export of cyclin D1. Oncogene. 25:6291–6303. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Moreno-Bueno G, Rodriguez-Perales S,
Sanchez-Estevez C, et al: Cyclin D1 gene (CCND1) mutations
in endometrial cancer. Oncogene. 22:6115–6118. 2003. View Article : Google Scholar
|
|
20
|
Minaguchi T, Yoshikawa H, Oda K, et al:
PTEN mutation located only outside exons 5, 6, and 7 is an
independent predictor of favorable survival in endometrial
carcinomas. Clin Cancer Res. 7:2636–2642. 2001.PubMed/NCBI
|
|
21
|
Tanikawa M, Wada-Hiraike O, Nakagawa S, et
al: Multifunctional transcription factor TFII-I is an activator of
BRCA1 function. Br J Cancer. 104:1349–1355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alt JR, Cleveland JL, Hannink M and Diehl
JA: Phosphorylation-dependent regulation of cyclin D1 nuclear
export and cyclin D1-dependent cellular transformation. Genes Dev.
14:3102–3114. 2000. View Article : Google Scholar
|
|
23
|
Gladden AB, Woolery R, Aggarwal P, Wasik
MA and Diehl JA: Expression of constitutively nuclear cyclin D1 in
murine lymphocytes induces B-cell lymphoma. Oncogene. 25:998–1007.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hall M and Peters G: Genetic alterations
of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human
cancer. Adv Cancer Res. 68:67–108. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bali A, O’Brien PM, Edwards LS, Sutherland
RL, Hacker NF and Henshall SM: Cyclin D1, p53, and
p21Waf1/Cip1 expression is predictive of poor clinical
outcome in serous epithelial ovarian cancer. Clin Cancer Res.
10:5168–5177. 2004.
|
|
27
|
Ogino S, Nosho K, Irahara N, et al: A
cohort study of cyclin D1 expression and prognosis in 602 colon
cancer cases. Clin Cancer Res. 15:4431–4438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bodrug SE, Warner BJ, Bath ML, Lindeman
GJ, Harris AW and Adams JM: Cyclin D1 transgene impedes lymphocyte
maturation and collaborates in lymphomagenesis with the myc gene.
EMBO J. 13:2124–2130. 1994.PubMed/NCBI
|
|
29
|
Lovec H, Grzeschiczek A, Kowalski MB and
Moroy T: Cyclin D1/bcl-1 cooperates with myc genes in the
generation of B-cell lymphoma in transgenic mice. EMBO J.
13:3487–3495. 1994.PubMed/NCBI
|
|
30
|
Lovec H, Sewing A, Lucibello FC, Muller R
and Moroy T: Oncogenic activity of cyclin D1 revealed through
cooperation with Ha-ras: link between cell cycle control and
malignant transformation. Oncogene. 9:323–326. 1994.PubMed/NCBI
|
|
31
|
Uchimaru K, Endo K, Fujinuma H, Zukerberg
L, Arnold A and Motokura T: Oncogenic collaboration of the cyclin
D1 (PRAD1, bcl-1) gene with a mutated p53 and an activated ras
oncogene in neoplastic transformation. Jpn J Cancer Res.
87:459–465. 1996. View Article : Google Scholar : PubMed/NCBI
|
